Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cervarix Gets One Up On Gardasil In Cross-Protection: HPV-31 In FDA Approval

Executive Summary

GlaxoSmithKline's effort to make its bivalent human papillomavirus vaccine, Cervarix, into a multivalent product through proof of cross protection against additional HPV virus strains achieved a partial, one-virus, success at FDA
Advertisement

Related Content

Gardasil Faces Another Safety Study, Looking At Four Rare AEs
Regulatory News, In Brief
Regulatory News, In Brief
Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions
Gardasil For Males Gets FDA OK; Next Up, Cost-Effectiveness Questions
Cervarix Passes Safety Hurdles; FDA Ponders Breadth of Protection Claim

Topics

Advertisement
UsernamePublicRestriction

Register

PS051575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel